Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alona Zer

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Oncology|July 11, 2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerOded Jacobi, Yosef Landman, Daniel Reinhorn, et al.
Asia-Pacific Journal of Clinical Oncology|August 8, 2020
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancerOded Icht, Liran Domachevsky, David Groshar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer DrugsDiogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
Frontiers in Oncology|March 29, 2021
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase InhibitorsElizabeth Dudnik, Jair Bar, Assaf Moore, et al.
International Journal of Cancer|September 3, 2020
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidenceElizabeth Dudnik, Mor Moskovitz, Abed Agbarya, et al.
Oncoimmunology|February 8, 2021
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, et al.
Thoracic Cancer|April 24, 2023
Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literatureItamar Averbuch, Roi Tschernichovsky, Oded Icht, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
Scientific Reports|May 16, 2019
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)Zachary Veitch, Alona Zer, Herbert Loong, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Oncology|July 11, 2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerOded Jacobi, Yosef Landman, Daniel Reinhorn, et al.
Asia-Pacific Journal of Clinical Oncology|August 8, 2020
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancerOded Icht, Liran Domachevsky, David Groshar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer DrugsDiogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
Frontiers in Oncology|March 29, 2021
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase InhibitorsElizabeth Dudnik, Jair Bar, Assaf Moore, et al.
International Journal of Cancer|September 3, 2020
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidenceElizabeth Dudnik, Mor Moskovitz, Abed Agbarya, et al.
Oncoimmunology|February 8, 2021
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, et al.
Thoracic Cancer|April 24, 2023
Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literatureItamar Averbuch, Roi Tschernichovsky, Oded Icht, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
Scientific Reports|May 16, 2019
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)Zachary Veitch, Alona Zer, Herbert Loong, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein, et al.
Pageof 10